SARS-CoV-2: Current Therapeutics Human and Veterinary Medicine

Supplemental Files
Date
2020-01-01
Authors
Garcia, Andrea
Journal Title
Journal ISSN
Volume Title
Publisher
Altmetrics
Authors
Research Projects
Organizational Units
Biomedical Sciences
Organizational Unit
Journal Issue
Series
Abstract

The Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2, was first reported in Wuhan City, China, in December 2019. Health and environmental risk factors are crucial in this current pandemic, yet it is essential to note that even though individuals of all ages are susceptive to this virus, there are risk factors associated with developing the severe disease. It is also eminent to establish the human-animal interaction by tackling important past pathogenic viruses such as SARS-CoV and MERS-CoV and its zoonotic links. In need of a clinically established management for this outbreak, approved drugs' therapeutic interventions could help treat this disease, targeting its replication. The need to resolve the current pandemic of COVID-19 epitomizes the need for a different approach, drug repurposing. Characterization of artificial intelligence created by predicted models and structures could alleviate COVID-19; it has been used not only in the development of drugs but also in tackling screening, treatment, and contact tracing. This review presents pathogenesis, transmission, and the analysis of drug repositioning in both human and veterinary medicine of SARS-CoV-2 to delve into practical approaches to manage this disease.

Description
Keywords
COVID-19, SARS-CoV-2, Drug Repurposing, Drug Repositioning, COVID-19 Pandemic, Current Therapeutics, coronavirus
Citation
DOI
Source